Review of the ATHOS 3 trial
Northwestern EM Blog
FEBRUARY 14, 2022
The primary outcome of the study was the response in MAP three hours after the start of angiotensin II infusion. It showed improvement in blood pressure which is a clinically important parameter but not a patient-oriented outcome. NEJM 2008; 358(9): 877 – 87. Crit Care 2014; 18(5): 534. PMID: 25286986 Russell JA et al.
Let's personalize your content